Author:
Younis Samaira,Latysheva Nina V.,Danilov Alexey B.,Ashina Messoud
Reference82 articles.
1. An optional second dose of ubrogepant is effective in achieving 2-hour pain freedom in the acute treatment of migraine [Abstract no. P112];Ailani;Headache,2019
2. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial;Ailani;Headache,2020
3. Atogepant for the preventive treatment of migraine;Ailani;N Engl J Med,2021
4. Ubrelvy, Package insert;Allergan USA Inc.,2019
5. Ubrogepant is not associated with clinically meaningful elevations of alanine aminotransferase in healthy adult males;Ankrom;Clin Transl Sci,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献